Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, received a notice from the State Drug Administration to approve the launch of a Class 1 new drug independently developed by the company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.